Shining a light in eye care
BioLight Life Sciences’ key products are IOPtiMate, a laser-based surgical device to treat moderate to advanced glaucoma, and VS-101, an extended-dose drug implant in Phase I/IIa trials to treat glaucoma. IOPtiMate was launched mainly in the EU and China in late 2014 and a US strategy will be determined in H216. BioLight is also advancing TeaRx as a diagnostic product for dry eye syndrome (DES). The company had NIS36.7m in net cash at 30 June 2016 and we derive an rNPV valuation of NIS90.5-97.6m.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.